GlassScriptPhysician profile
Massiel Sarmiento
NPI 1386049633
$580.08
in general payments reported to CMS, 2019-2025
14 companies · $55.91 in 2025
The $55.91 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26.82 · 2020: $69.08 · 2021: $141 · 2022: $106 · 2023: $149 · 2024: $32.08 · 2025: $55.91.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $236.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $112.67 | 2019-2023 | Auvi-Q |
| Genentech USA, INC. | $100.86 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $70.40 | 2021-2025 | Gardasil 9, Vaxneuvance, Enflonsia |
| Aytu Biopharma, INC. | $58.94 | 2020-2022 | |
| Sanofi Pasteur INC. | $46.87 | 2023 | |
| Phadia US INC. | $41.09 | 2023-2025 | Immunocap |
| Cranial Technologies, INC | $26.28 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $24.01 | 2022 | |
| Viiv Healthcare Company | $20.69 | 2025 | Apretude |
| Verrica Pharmaceuticals INC. | $18.92 | 2024 | Ycanth |
| Neos Therapeutics, LP | $18.57 | 2021 | |
| Hologic Sales and Service, LLC | $14.88 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $13.16 | 2024 | Flumist Quadrivalent |
| Seqirus USA INC | $12.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Massiel Sarmiento listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.